Pharmacogenetics and pharmacovigilance

Drug Safety

Volumn 32, Issue 3, 2009, Pages 265-270

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ALLELE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MORBIDITY; MORTALITY; NOTE; PATIENT CARE; PHARMACIST; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG MONITORING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 63849202760     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932030-00009     Document Type: Note

References (33)

1. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49
2. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37
3. van Puijenbroek EP, Conemans J, van Grootheest AC. Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands. Drug Saf 2009; 32 (3): 255-64
4. Hutchinson TA, Lane DA. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol 1989; 42: 5-16
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
6. Melville A. Set and serendipity in the detection of drug hazards. Soc Sci Med 1984; 19: 391-6
7. Brody HB, Brody D. Three perspectives on the placebo response: expectancy, conditioning, and meaning. Adv Mind Body Med 2000; 16: 216-32
8. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychological Bull 2004; 130: 324-40
9. Krell HV, Leuchter AF, Morgan M, et al. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry 2004; 65: 1174-9
10. Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 622-7
11. Kirsch I. Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd (2004). Psychological Bull 2004; 130: 341-3
12. Jaeger GT, Larsen S, Moe L. Stratification, blinding and placebo effect in a randomized, double blind, placebocontrolled clinical trial of gold bead implantation in dogs with hip dysplasia. Acta Vet Scand 2005; 46: 57-68
13. Li W, Howard JD, Parrish TB, et al. Aversive learning enhances perceptual and cortical discrimination of indiscriminable odor cues. Science 2008; 319: 1842-5
14. Malhotra AK. Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain.Neurotox Res 2004; 6: 51-6
15. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69: 1416-22
16. Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009; 29: 65-8
17. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2009; 29: 16-20
18. Thelma BK, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9: 1285-306
19. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164: 1530-8
20. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Disc 2007; 6: 904-16
21. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22: 298-305
22. Tomalik-Scharte D, Lazar A, Fuhr U, et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8: 4-15
23. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-9
24. Matchar DB, Thakur ME, Grossman I, et al. Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence report/technology assessment no. 146. (Prepared by the Duke Evidence-Based Practice Center under contract no. 290-02-0025.) Rockville (MD): Agency for Healthcare Research and Quality, 2007 Jan. AHRQ publication no. 07-E002
25. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
26. Wester K, Jonsson AK, Spigset O, et al. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65: 573-9
27. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587-91
28. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B1502 allele in Thai population. Epilepsia 2008; 49: 2087-91
29. Motsinger AA, Ritchie MD, Reif DM. Novel methods for detecting epistasis in Pharmacogenomics studies. Pharmacogenomics 2007; 8: 1229-41
30. Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA 2008; 299: 1345-50
31. Eckman MH, Rosand J, Greenberg SM, et al. Costeffectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150: 73-83
32. Moldrup C. Ethical, social, and legal implications of pharmacogenomics: a critical review. Comm Genet 2001; 4: 204-14
33. Phillips KA, Van Bebber SL. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev 2006; 63: 301-26